Drug Profile
Research programme: CORE-2 GlcNAc transferase inhibitors - BTG
Alternative Names: BGC 200402; CORE-2 GlcNAc transferase inhibitors research programme - BTG; Diabetic retinopathy therapy research programme - BTGLatest Information Update: 21 Aug 2019
Price :
$50
*
At a glance
- Originator Kings College London
- Developer BTG
- Class Small molecules
- Mechanism of Action Core 2 GlcNAc transferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atherosclerosis; Diabetic retinopathy; Inflammation
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 16 Jul 2016 No recent reports of development identified for preclinical development in Atherosclerosis in United Kingdom
- 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetic-retinopathy in United Kingdom